"Psychomotor agitation"

Exploring actigraphy as a digital phenotyping measure: A study on differentiating psychomotor agitation and retardation in depression. Psychomotor activity stands out as a crucial symptom in characterizing behaviors associated with depression. This study aims to explore the potential of actigraphy as a tool for digital phenotyping in characterizing symptoms of psychomotor agitation and retardation, which are clinically challenging dimensions to capture, in patients diagnosed with major depressive episode (MDE) according to DSM-5 criteria. We compared rest-activity circadian rhythm biomarkers measured by the Motion Watch 8 actigraphy between 58 (78.4%) patients with MDE and psychomotor retardation (PMR), and 16 (21.6%) patients with MDE and psychomotor agitation (PMA), according to DSM-5

Brazilian guidelines for the management of psychomotor agitation. Part 1. Non-pharmacological approach To present the essential guidelines for non-pharmacological management of patients with psychomotor agitation in Brazil. These guidelines were developed based on a systematic review of articles published from 1997 to 2017, retrieved from MEDLINE (PubMed), Cochrane Database of Systematic Review these techniques and overcome difficulties if the verbal approach fails. It is important that healthcare professionals be trained in non-pharmacological management of patients with psychomotor agitation as part of the requirements for a degree and graduate degree. The non-pharmacological management of agitated patients should follow the hierarchy of less invasive to more invasive and coercive measures, starting

Medium- and high-intensity rTMS reduces psychomotor agitation with distinct neurobiologic mechanisms Definitive data are lacking on the mechanism of action and biomarkers of repetitive transcranial magnetic stimulation (rTMS) for the treatment of depression. Low-intensity rTMS (LI-rTMS) has demonstrated utility in preclinical models of rTMS treatments but the effects of LI-rTMS in murine models targeted metabolomics evaluated with ingenuity pathway analysis (IPA). MI-rTMS and HI-rTMS attenuated psychomotor agitation but only MI-rTMS increased BDNF and neurogenesis levels. HI-rTMS normalized the plasma concentration of α-amino-n-butyric acid and 3-methylhistidine. IPA revealed significant changes in glutamine processing and glutamate signaling in the OB model and following MI-rTMS and HI-rTMS

Successful treatment for psychomotor agitation in neuromyelitis optica spectrum disorder with trazodone–risperidone combination: a case report Neuromyelitis optica (NMO) is a relapsing disease that typically affects the spinal cord and optic nerves. So far, a few studies have reported pharmacologic treatment for psychiatric symptoms in patients with NMO spectrum disorder (NMOSD). However , no literature has described psychomotor agitation associated with the disease and its treatment. We report an 84-year-old woman with NMOSD whose psychomotor agitation was effectively treated with a combination of trazodone and risperidone. Our observation suggests the ability of augmentation of antipsychotic drugs with antidepressants to ameliorate psychotic symptoms associated with NMOSD.

Psychomotor Agitation Following Treatment with Hydroxychloroquine We describe the case of an elderly woman with elderly-onset rheumatoid arthritis, where the use of 4 mg/kg/day of hydroxychloroquine (HCQ) was followed by the onset of psychomotor agitation with marked physical and verbal violence towards her partner, including throwing objects at her partner. No disturbance in sleep and no anxiety , nervousness, or irritability had emerged before the onset of her psychomotor agitation. The disappearance of agitation following targeted pharmacologic intervention and HCQ interruption, its re-onset after reintroduction of the drug, and the high score (9) of Naranjo's algorithm are surely linked to the existence of a causal relationship between HCQ and psychomotor agitation. HCQ may produce undesirable

Psychomotor agitation in major depressive disorder is a predictive factor of mood-switching. The relationship between psychomotor agitation in unipolar depression and mood-switching from depression to manic, hypomanic and mixed states has been controversial. We investigated the future risk of initial mood-switching as a function of psychomotor agitation in unipolar depression. We identified 189 were conducted to examine the risk of mood-switching by psychomotor agitation. During follow-up, mood-switching occurred in 20.3% of the agitated patients and 7.0% of the non-agitated patients. In the Kaplan-Meier survival estimates for time to incidence of mood-switching with agitated or non-agitated patients, the cumulative probability of developing mood-switching for agitated patients was higher

Are low doses of antipsychotics effective in the management of psychomotor agitation? A randomized, rated-blind trial of 4 intramuscular interventions. Psychomotor agitation can be associated with a wide range of medical conditions. Although clinical practice advocates the use of several drugs for the management of psychomotor agitation, there are still very few controlled studies comparing the profiles of action and the adverse effects of different drugs that induce tranquilization. The purpose of this study was to compare the efficacy and safety of 4 low-dose pharmacological interventions used to control psychomotor agitation guided by the clinical response. Using a randomized, rated-blind design, 100 agitated patients were assigned to receive 1 of 4 treatments: haloperidol (2.5 mg

Intramuscular aripiprazole in the acute management of psychomotor agitation. To assess acute efficacy and safety of 9.75 mg of intramuscular (IM) injections of the atypical antipsychiatric aripiprazole in patients with schizophrenia or bipolar disorder and acute agitation. Open-label trial of IM injections of aripiprazole and 24-hour monitoring of clinical response in patients with major

-5 requires the identification of either (1) depressed mood most of the day, on a daily basis, with individuals reporting hopelessness, worthlessness, or appearing weepy; or (2) noticeably less attentiveness or desire, alongside at least five of the symptoms, for at least 2 weeks (criteria include: weight loss or gain, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue, feeling

by a period of at least two weeks in which a depressed mood and/or diminished interest or pleasure in activities are experienced nearly every day, alongside other symptoms (changes in weight or appetite, disruption to normal sleep patterns, psychomotor agitation or retardation, loss of energy, reduced ability to think or concentrate, feelings of worthlessness or excessive guilt, and recurrent thoughts

indecisiveness. * Low self-esteem or excessive and inappropriate guilt. * Hopelessness about the future. * Recurrent thoughts of death, recurrent suicidal ideation or evidence of attempted suicide. * Significantly disrupted sleep or excessive sleep. * Significant change in appetite. * Psychomotor agitation or retardation. * Reduced energy, fatigue, or marked tiredness after minimal exertion. * The symptoms

, excessive guilt, hopelessness about the future, recurrent thoughts of death, self-harming behaviours, or suicidal ideation. * Neurovegetative symptoms: These include disrupted or excessive sleep, changes in appetite or expected weight patterns, psychomotor agitation or retardation, and lack of energy. * ICD-11 also states that symptoms should not be a manifestation of another medical condition, or a side

hallucinations/illusions, psychomotor agitation, and/or anxiety, which occur following cessation or reduction in alcohol use that has been heavy and prolonged (DSM-5). Serious complications include seizures and delirium tremens. Withdrawal presents similarly when pregnant as when not pregnant, but the consequences of withdrawal can be more serious in the context of pregnancy. Due to the significant risks

of conditions that are delirium, psychomotor agitation and physiological excitation” (Hoffman L, 2009). ACEP went on to say that while the term had “long been the sole purview of medical examiners, largely because the syndrome is only diagnosed on autopsy”, the formal recognition of ‘ExD’ marked “an initial step towards identifying its causes and preventing deaths that can occur in these patients”. First ., 2009; Baldwin S, Hall C et al., 2016; Baldwin S, Hall C et al., 2018).Furthermore, although the ACEP white paper referred to the “hallmark triad of conditions that are delirium, psychomotor agitation and physiological excitation”, features of delirium have not been assessed in many of the case reports and case series. This includes the Canadian study of police/public encounters, which calls